JP2014506583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506583A5 JP2014506583A5 JP2013554652A JP2013554652A JP2014506583A5 JP 2014506583 A5 JP2014506583 A5 JP 2014506583A5 JP 2013554652 A JP2013554652 A JP 2013554652A JP 2013554652 A JP2013554652 A JP 2013554652A JP 2014506583 A5 JP2014506583 A5 JP 2014506583A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- receptor modulator
- composition according
- neurotransmitter
- immunomodulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940075993 receptor modulator Drugs 0.000 claims description 67
- 102000004108 Neurotransmitter Receptors Human genes 0.000 claims description 49
- 108090000590 Neurotransmitter Receptors Proteins 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 35
- 208000016192 Demyelinating disease Diseases 0.000 claims description 31
- 239000002955 immunomodulating agent Substances 0.000 claims description 28
- 229940121354 immunomodulator Drugs 0.000 claims description 28
- 230000002584 immunomodulator Effects 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 22
- 229960001081 benzatropine Drugs 0.000 claims description 16
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 16
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 12
- 229960002052 salbutamol Drugs 0.000 claims description 12
- 102000003840 Opioid Receptors Human genes 0.000 claims description 10
- 108090000137 Opioid Receptors Proteins 0.000 claims description 10
- 230000001919 adrenal effect Effects 0.000 claims description 10
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 10
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 10
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 10
- 229960002881 clemastine Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229960000556 fingolimod Drugs 0.000 claims description 10
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 229940121891 Dopamine receptor antagonist Drugs 0.000 claims description 8
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims description 8
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 8
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 8
- 239000000739 antihistaminic agent Substances 0.000 claims description 8
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 8
- 239000003149 muscarinic antagonist Substances 0.000 claims description 8
- 229960004017 salmeterol Drugs 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229960002324 trifluoperazine Drugs 0.000 claims description 8
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 8
- 239000000674 adrenergic antagonist Substances 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 238000011287 therapeutic dose Methods 0.000 claims description 6
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 5
- 206010012305 Demyelination Diseases 0.000 claims description 5
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 5
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 5
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 5
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 5
- 206010028570 Myelopathy Diseases 0.000 claims description 5
- 208000003435 Optic Neuritis Diseases 0.000 claims description 5
- 206010036105 Polyneuropathy Diseases 0.000 claims description 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 5
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 5
- 201000004339 autoimmune neuropathy Diseases 0.000 claims description 5
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229960003776 glatiramer acetate Drugs 0.000 claims description 5
- 229960004461 interferon beta-1a Drugs 0.000 claims description 5
- 229960003161 interferon beta-1b Drugs 0.000 claims description 5
- 208000036546 leukodystrophy Diseases 0.000 claims description 5
- 229960001156 mitoxantrone Drugs 0.000 claims description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 5
- 229960005027 natalizumab Drugs 0.000 claims description 5
- 230000007824 polyneuropathy Effects 0.000 claims description 5
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 5
- 208000009174 transverse myelitis Diseases 0.000 claims description 5
- 210000004885 white matter Anatomy 0.000 claims description 5
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 4
- 229960003436 pentoxyverine Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000023105 myelination Effects 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 claims description 2
- KQWVAUSXZDRQPZ-UMTXDNHDSA-N 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enyl-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 claims description 2
- 229930003347 Atropine Natural products 0.000 claims description 2
- 102000015554 Dopamine receptor Human genes 0.000 claims description 2
- 108050004812 Dopamine receptor Proteins 0.000 claims description 2
- 102000000543 Histamine Receptors Human genes 0.000 claims description 2
- 108010002059 Histamine Receptors Proteins 0.000 claims description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 2
- MGVRNMUKTZOQOW-UHFFFAOYSA-N N'-[2-(3,4-dichlorophenyl)ethyl]-N,N,N'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)CCC1=CC=C(Cl)C(Cl)=C1 MGVRNMUKTZOQOW-UHFFFAOYSA-N 0.000 claims description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 2
- 229960000396 atropine Drugs 0.000 claims description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 2
- 229960001888 ipratropium Drugs 0.000 claims description 2
- 229960002508 pindolol Drugs 0.000 claims description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical group CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 238000007910 systemic administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161444666P | 2011-02-18 | 2011-02-18 | |
| US61/444,666 | 2011-02-18 | ||
| PCT/US2012/025712 WO2012112933A1 (en) | 2011-02-18 | 2012-02-17 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017026806A Division JP2017132769A (ja) | 2011-02-18 | 2017-02-16 | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506583A JP2014506583A (ja) | 2014-03-17 |
| JP2014506583A5 true JP2014506583A5 (enExample) | 2015-04-09 |
| JP6133790B2 JP6133790B2 (ja) | 2017-05-24 |
Family
ID=46672968
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554652A Expired - Fee Related JP6133790B2 (ja) | 2011-02-18 | 2012-02-17 | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| JP2017026806A Pending JP2017132769A (ja) | 2011-02-18 | 2017-02-16 | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| JP2019211952A Pending JP2020040981A (ja) | 2011-02-18 | 2019-11-25 | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017026806A Pending JP2017132769A (ja) | 2011-02-18 | 2017-02-16 | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| JP2019211952A Pending JP2020040981A (ja) | 2011-02-18 | 2019-11-25 | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9592288B2 (enExample) |
| EP (2) | EP2675893B1 (enExample) |
| JP (3) | JP6133790B2 (enExample) |
| DK (1) | DK2675893T3 (enExample) |
| ES (1) | ES2716865T3 (enExample) |
| WO (1) | WO2012112933A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| JP2014528706A (ja) * | 2011-08-07 | 2014-10-30 | カディマステム リミテッド | 成熟、生存及びミエリン形成に作用する薬剤を同定する方法 |
| EP2724723A1 (en) * | 2012-10-25 | 2014-04-30 | Universitätsklinikum Hamburg-Eppendorf | Tegaserod for use in the treatment of nerve injuries |
| ES2859553T3 (es) * | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
| US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
| BR112015022896B1 (pt) * | 2013-03-15 | 2022-08-23 | Chongxi Yu | Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN106061497A (zh) * | 2013-12-20 | 2016-10-26 | 曼尼托巴大学 | 用于治疗周围神经病变的方法和组合物 |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| FR3029113A1 (fr) * | 2014-12-02 | 2016-06-03 | Univ Paris-Sud | Composes pour le traitement des maladies mitochondriales |
| EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| CA3015702A1 (en) * | 2015-09-02 | 2017-03-09 | Trevena, Inc. | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| CN107286031B (zh) * | 2016-04-05 | 2019-08-09 | 上海医药工业研究院 | 2-二乙氨基-1-甲基乙基-7-环己基-7-氧庚酸酯的制备方法 |
| JP2019535265A (ja) * | 2016-11-14 | 2019-12-12 | メモリアル スローン ケタリング キャンサー センター | 幹細胞由来シュワン細胞 |
| BR112019016827A2 (pt) | 2017-02-17 | 2020-04-07 | Trevena Inc | compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos |
| JP7185633B2 (ja) | 2017-02-17 | 2022-12-07 | トレベナ・インコーポレイテッド | ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法 |
| BR112019021435A2 (pt) * | 2017-04-13 | 2020-05-05 | Univ Leland Stanford Junior | sistema de cultura neural 3d personalizado para gerar oligodendrócitos humanos e estudar mielinação in vitro |
| US11478467B2 (en) * | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| EP3412294A1 (en) | 2017-06-08 | 2018-12-12 | Universite De Fribourg | Hdac1/2 activator for promoting and/or accelerating myelination and/or remyelination |
| AU2018411573A1 (en) * | 2018-03-08 | 2020-10-01 | The Scripps Research Institute | Methods for promoting myelination and for treating demyelinating diseases |
| HUE069820T2 (hu) | 2018-03-08 | 2025-04-28 | Victoria Link Ltd | Nalfurafin alkalmazása demielinizációs betegségek kezelésére |
| WO2019195742A1 (en) * | 2018-04-05 | 2019-10-10 | Frequency Therapeutics, Inc. | Compositions and methods for increasing remyelination |
| US20240252461A1 (en) * | 2018-04-13 | 2024-08-01 | Mordechai Chevion | Compositions and methods for treatment of demyelination |
| CN108624560B (zh) * | 2018-06-01 | 2022-04-08 | 南京艾尔普再生医学科技有限公司 | 一种分化培养基及少突胶质前体细胞的制备方法 |
| JP2021527712A (ja) * | 2018-06-14 | 2021-10-14 | キュラセン セラピューティクス インコーポレイテッド | 神経系疾患および障害を、診断、監視、および治療するための方法 |
| CA3115269A1 (en) * | 2018-10-09 | 2020-04-16 | Medicinova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| CN111317754B (zh) * | 2018-12-13 | 2022-02-18 | 泰州医药城国科化物生物医药科技有限公司 | 一种北豆根总碱的制备方法及应用 |
| CN109942592B (zh) * | 2019-05-09 | 2020-07-14 | 江西中医药大学 | 一种新原阿片碱型生物碱及其制备方法和应用 |
| EP3797769A1 (fr) * | 2019-09-25 | 2021-03-31 | Fontès, M. Michel | Composition a usage therapeutique |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| JP7704364B2 (ja) * | 2020-01-22 | 2025-07-08 | テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー | 脊髄損傷の治療及び移動運動機能の改善のためのエレトリプタン臭化水素酸塩 |
| JP2023531358A (ja) * | 2020-05-01 | 2023-07-24 | ザ チルドレンズ メディカル センター コーポレーション | ミエリン形成を促進する組成物および方法 |
| WO2022242766A1 (zh) * | 2021-05-21 | 2022-11-24 | 成都文鼎科技发展有限公司 | 一种调节神经病变的方法 |
| WO2023081458A1 (en) * | 2021-11-08 | 2023-05-11 | Rutgers, The State University Of New Jersey | Systems and methods for diagnosis and/or treating demyelinating neuropathy |
| WO2023171736A1 (ja) | 2022-03-11 | 2023-09-14 | 帝人ファーマ株式会社 | 免疫調節性物質と組み合わせて使用される、ビタミンｄ誘導体またはその医薬上許容される塩もしくは溶媒和物を含有する医薬 |
| WO2023225206A1 (en) | 2022-05-18 | 2023-11-23 | The Scripps Research Institute | Method for enhancing remyelination via co-administration of muscarinic receptor antagonists and vitamin d analogues |
| CN116115760A (zh) * | 2022-12-15 | 2023-05-16 | 浙江大学 | Eed抑制剂在制备治疗神经免疫性疾病药物中的应用 |
| WO2025049588A1 (en) * | 2023-08-29 | 2025-03-06 | The Trustees Of Indiana University | Novel treatments for optic neuropathies and glaucoma |
| CN117599054B (zh) * | 2024-01-24 | 2024-03-29 | 成都第一制药有限公司 | 一种治疗假性近视的药物组合物及其用途 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| EP0584185B1 (en) | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| FR2710265B1 (fr) | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| DE19541260A1 (de) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| JPH10218867A (ja) | 1997-02-10 | 1998-08-18 | Pola Chem Ind Inc | ドーパミン再取り込み阻害剤 |
| EA002806B1 (ru) | 1997-09-11 | 2002-10-31 | Нюкомед Данмарк А/С | Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid) |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6248864B1 (en) | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| WO2000001376A2 (en) * | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| CN1406126A (zh) | 1998-10-01 | 2003-03-26 | 诺瓦提斯公司 | 新型缓释口服制剂 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2792527B1 (fr) | 1999-04-22 | 2004-08-13 | Ethypharm Lab Prod Ethiques | Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques |
| US6541020B1 (en) | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| DE60036874T2 (de) | 1999-09-02 | 2008-06-26 | Nostrum Pharmaceuticals Inc. | Pellet formulierung mit gesteuerter freisetzung |
| US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6080736A (en) | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6482439B2 (en) | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6608101B1 (en) | 2000-06-20 | 2003-08-19 | Atherogenics, Inc. | 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders |
| US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| DE60216419T2 (de) * | 2001-02-07 | 2007-09-27 | National Research Council Of Canada, Ottawa | Methode zur herstellung von pflanzensamen mit verändertem fibergehalt und veränderter samenschale |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| DE60322680D1 (de) | 2002-02-07 | 2008-09-18 | Univ Missouri | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen |
| CA2495386C (en) | 2002-08-14 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| AU2004224277A1 (en) * | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| JP2007530703A (ja) * | 2004-04-01 | 2007-11-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用 |
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| EP2073827A4 (en) * | 2006-11-03 | 2012-04-25 | Univ Northwestern | THERAPY FOR MULTIPLE SCLEROSIS |
| US20080286234A1 (en) | 2007-05-15 | 2008-11-20 | Eyink Daniel A | Method for treating demyelinating diseases |
| DK2173344T3 (en) * | 2007-06-29 | 2016-07-25 | Clarencew Pty Ltd | TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEURO PSYCHIATRIC DISORDERS USING ocular administration |
| US20100239528A1 (en) | 2007-07-20 | 2010-09-23 | Stem Cell Therapeutics Corp. | Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta |
| US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
| EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| PL2379067T3 (pl) | 2008-12-22 | 2016-02-29 | Novartis Ag | Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego |
| EP3061449A1 (en) * | 2009-09-29 | 2016-08-31 | Novartis AG | Dosage regimen of an s1p receptor modulator |
| US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
-
2012
- 2012-02-17 US US13/985,342 patent/US9592288B2/en active Active
- 2012-02-17 JP JP2013554652A patent/JP6133790B2/ja not_active Expired - Fee Related
- 2012-02-17 DK DK12747134.0T patent/DK2675893T3/en active
- 2012-02-17 ES ES12747134T patent/ES2716865T3/es active Active
- 2012-02-17 WO PCT/US2012/025712 patent/WO2012112933A1/en not_active Ceased
- 2012-02-17 EP EP12747134.0A patent/EP2675893B1/en active Active
- 2012-02-17 EP EP18208362.6A patent/EP3502236B1/en active Active
-
2015
- 2015-12-17 US US14/973,105 patent/US10660899B2/en active Active
-
2017
- 2017-01-27 US US15/418,572 patent/US10493080B2/en active Active
- 2017-02-16 JP JP2017026806A patent/JP2017132769A/ja active Pending
-
2019
- 2019-11-25 JP JP2019211952A patent/JP2020040981A/ja active Pending
-
2020
- 2020-04-08 US US16/843,832 patent/US11246873B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11207279B2 (en) | Application of R-ketamine and salt thereof as pharmaceuticals | |
| AU2007264031B2 (en) | S1P receptor modulators for treating multiple sclerosis | |
| JP2019517590A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2015520188A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2015509075A5 (enExample) | ||
| JP2015524423A5 (enExample) | ||
| JP2016504389A5 (enExample) | ||
| JP2013522231A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2016515137A5 (enExample) | ||
| JP2010500284A5 (enExample) | ||
| JP2015534990A5 (enExample) | ||
| JP2013536206A5 (enExample) | ||
| JP2020533402A5 (enExample) | ||
| RU2017126153A (ru) | Фармацевтическая комбинация | |
| JP2010538010A5 (enExample) | ||
| JP2013518061A5 (enExample) | ||
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2014521606A5 (enExample) | ||
| JP2015514771A5 (enExample) |